Generic Drug Industry Warned Of Impending Deficiency Letters For Pre-Filled Syringes
This article was originally published in The Gold Sheet
An official with the generic drug industry warned of a potential onslaught of ANDA deficiency letters going to manufacturers of generic drugs combined with needleless pre-filled glass syringes and connecting devices for not adhering to FDA guidance. FDA is now requiring more data to ensure the safety of these products, including human factors testing and performance testing.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.